

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222333 A1

- (51) **International Patent Classification:**
C07K 16/32 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/029517
- (22) **International Filing Date:**
28 April 2021 (28.04.2021)

- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/018,356 30 April 2020 (30.04.2020) US

- (71) **Applicant:** GENENTECH, INC. [US/US]; 1 DNA Way,
South San Francisco, California 94080-4990 (US).

- (72) **Inventors:** MULVIHILL, Melinda M; c/o Genentech,
Inc., 1 DNA Way, South San Francisco, California
94080-4990 (US). QUINN, John Gerard; c/o Genen-
tech, Inc., 1 DNA Way, South San Francisco, Califor-
nia 94080-4990 (US). STEFFEK, Micah; c/o Genen-
tech, Inc., 1 DNA Way, South San Francisco, California
94080-4990 (US). WANG, Weiru; c/o Genentech, Inc., 1
DNA Way, South San Francisco, California 94080-4990
(US). BRUNING, John; c/o Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080-4990 (US).
DAVIES, Christopher Williamson; c/o Genentech, Inc.,
1 DNA Way, South San Francisco, California 94080-4990
(US). EVANGELISTA, Marie; c/o Genentech, Inc., 1
DNA Way, South San Francisco, California 94080-4990
(US). KOERBER, James Thomas; c/o Genentech, Inc.,
1 DNA Way, South San Francisco, California 94080-4990
(US).

- (74) **Agent:** CLARK, Kevin M. et al.; c/o Genentech, Inc., 1
DNA Way, South San Francisco, California 94080-4990
(US).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2021/222333 A1

- (54) **Title:** KRAS SPECIFIC ANTIBODIES AND USES THEREOF

- (57) **Abstract:** Provided herein are anti-KRas antibodies that bind to mutant KRas-GDP and alkylated mutant KRas-GDP and methods of using the same. Also provided herein are method of screening for KRas inhibitors and methods of measuring binding of KRas to the antibodies described herein.